GOTHENBURG, Sweden, April 30, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces new number of shares and votes in the company.
The information in the press release is intended for investors.
The number of shares and votes in Isofol Medical AB (publ) has changed due to recently completed exercise of warrants of series TO1, including a top guarantee commitment (for further information, see the company’s press release on March 31, 2026). Through the exercise of warrants of series TO1 including the top guarantee commitment, which were registered with the Swedish Companies Registration Office in April 2026, the number of shares and votes in Isofol increased with a total of 39,384,399. Today, on the last trading day of the month, there are in total 320,491,623 shares and votes in Isofol.
For more information, please contact
Isofol Medical AB (publ)
Margareta Hagman, Chief Financial Officer
E-mail: margareta.hagman@isofolmedical.com
Phone: +46 (0) 738 73 34 18
This is information that Isofol Medical AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CEST on April 30, 2026.
About Isofol
Isofol Medical AB (publ) is a clinical stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. The company’s drug candidate arfolitixorin, a next generation folate treatment, is designed to enhance the efficacy of established standard treatments for several types of solid tumors. Arfolitixorin is currently being evaluated in phase Ib/II in colorectal cancer, the world’s third most common cancer, where there is a significant unmet medical need. Isofol is listed on Nasdaq Stockholm.